Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the long-term safety and efficacy of lubiprostone administration in participants with opioid-induced bowel dysfunction.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| All Participants | Experimental | Lubiprostone: 24 mcg capsule twice daily (BID) for 36 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lubiprostone 24 | Drug | 24 mcg capsules for oral administration |
|
| Measure | Description | Time Frame |
|---|---|---|
| Mean Weekly Spontaneous Bowel Movements (SBMs) Per Month | A Spontaneous Bowel Movement (SBM) is defined as any bowel movement (BM) that did not occur within the 24-hour period following use of a rescue medication. | Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, and 9 |
| Mean Weekly Bowel Movements (BMs) Per Month | A Bowel Movement (BM) is defined as any BM (whether spontaneous or not) | Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, and 9 |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants Classified as Monthly Responders | A weekly SBM frequency rate is calculated as (168 x Number of SBMs / Number of hours observed). A participant with an SBM frequency rate between 3 and 4 was considered a moderate responder. A subject with an SBM frequency rate higher than 4 was considered a full responder. If a subject was a moderate responder or full responder for at least half the weeks in a month, then he or she was considered a monthly responder. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Global Clinical Leader | Mallinckrodt | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Birmingham Pain Center | Birmingham | Alabama | 35242 | United States | ||
| Simon Williamson Clinic, PC |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Participants were enrolled from 4 December 2007 to 29 September 2009 at 137 recruitment sites in the United States (n=134) and Canada (n=3)
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Lubiprostone | Lubiprostone: 24 mcg capsules twice daily (BID) for 36 weeks |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Months 1, 2, 3, 4, 5, 6, 7, 8, and 9 |
| Straining Associated With Spontaneous Bowel Movements by Month | Participants rate the straining associated with the SBM on a scale where 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe The highest score is 4, and lower scores are better. | Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, and 9 |
| Stool Consistency of Spontaneous Bowel Movements by Month | Participants rate each spontaneous bowel movement on a scale where 0 = very loose, 1 = loose, 2 = normal, 3 = hard, 4 = very hard (little balls) The highest score is 4, but the best score is 2. | Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, and 9 |
| Constipation Severity by Month | Participants rate the severity of their constipation on a scale where 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe. The highest score is 4, but the best score is 0. | Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, and 9 |
| Abdominal Bloating by Month | Participants rate their bloating on a scale where 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe. The highest score is 4, but the best score is 0. | Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, and 9 |
| Abdominal Discomfort by Month | Participants rate their abdominal discomfort on a scale where 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe. The highest score is 4, but the best score is 0. | Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, and 9 |
| Bowel Habit Regularity by Month | Participants rate their bowel habit regularity on a balanced scale of 1 to 7 where 1=Very Regular and 7=Very Irregular. The highest score is 7, but the best score is 1. | Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, and 9 |
| Treatment Effectiveness by Month | Participants rate treatment effectiveness on a scale where 0 = not at all effective, 1 = a little bit effective, 2 = moderately effective, 3 = quite a bit effective, 4 = extremely effective. The highest and best score is 4. | Months 1, 2, 3, 4, 5, 6, 7, 8, and 9 |
| Mean Weekly Complete SBMs by Month | Participants rate each SBM as complete if their bowels feel completely empty after the SBM | Months 1, 2, 3, 4, 5, 6, 7, 8, and 9 |
| Mean Weekly Complete BMs by Month | Participants rate each BM as complete if their bowels feel completely empty after the BM | Months 1, 2, 3, 4, 5, 6, 7, 8, and 9 |
| Hueytown |
| Alabama |
| 35023 |
| United States |
| Alabama Orthopedic Clinic | Mobile | Alabama | 36608 | United States |
| Clinical Research Advantage, Inc./ Mesa Family Medical Center | Mesa | Arizona | 85203 | United States |
| Redpoint Research | Phoenix | Arizona | 85029 | United States |
| HOPE Research Institute | Phoenix | Arizona | 85050 | United States |
| Clinical Research Advantage, Inc. | Phoenix | Arizona | 85128 | United States |
| Clinical Research Advantage, Inc. / East Valley Family Physicians, PLC | Tempe | Arizona | 85222 | United States |
| Clinical Research Advantage, Inc. | Tempe | Arizona | 85282 | United States |
| Premiere Pharamaceutical Research, LLC | Tempe | Arizona | 85282 | United States |
| Genova Clinical Research | Tucson | Arizona | 85704 | United States |
| Verona Clinical Research, Inc. | Tucson | Arizona | 85710 | United States |
| Advanced Clinical Therapeutics, LLC | Tucson | Arizona | 85712 | United States |
| Paradigm Clinical Research, Inc. | Tucson | Arizona | 85712 | United States |
| Quality of Life Medical & Research Center, LLC | Tucson | Arizona | 85712 | United States |
| Wilson and Charani | Tucson | Arizona | 85741 | United States |
| Arkansas Pain Research | Hot Springs | Arkansas | 71913 | United States |
| Teton Research, LLC | Little Rock | Arkansas | 72205 | United States |
| Advanced Clinical Research Institute | Anaheim | California | 92801 | United States |
| Orange County Clinical Trials | Anaheim | California | 92801 | United States |
| Advanced Pain Institute | Arcadia | California | 91007 | United States |
| Impact Clinical Trials | Beverly Hills | California | 90036 | United States |
| Digestive and Liver Disease Specialists | Garden Grove | California | 92840 | United States |
| RX Clinical Research, Inc. | Garden Grove | California | 92843 | United States |
| Loma Linda University | Loma Linda | California | 92354 | United States |
| Pasadena Rehabilitation Institute | Pasadena | California | 91105 | United States |
| Northern California Research Corporation | Sacramento | California | 95831 | United States |
| Rider Research Group | San Francisco | California | 94117 | United States |
| ShahShreenath Clinical Service | Yorba Linda | California | 92886 | United States |
| Clinicos, LLC | Colorado Springs | Colorado | 80904 | United States |
| Lynn Institute of the Rockies | Colorado Springs | Colorado | 80907 | United States |
| Advanced Diagnostic Pain Treatment Center | New Haven | Connecticut | 06511 | United States |
| Meridien Research | Brooksville | Florida | 34601 | United States |
| Century Clinical Research Inc | Daytona Beach | Florida | 32117 | United States |
| International Medical Research | Daytona Beach | Florida | 32117 | United States |
| Clinical Physiology Associates/Clinical Study Center | Fort Myers | Florida | 33916 | United States |
| Southeastern Integrated Medical, PL dba Florida | Gainesville | Florida | 32607 | United States |
| Century Clinical Research | Holly Hill | Florida | 32117 | United States |
| Florida Institute of Medical Research | Jacksonville | Florida | 32257 | United States |
| Drug Study Institute | Jupiter | Florida | 33458 | United States |
| Sunrise Medical Research, Inc. | Lauderdale Lakes | Florida | 33319 | United States |
| Kenneth W. Ponder, MD, PA | Niceville | Florida | 32578 | United States |
| North Miami Research Inc. | North Miami | Florida | 33161 | United States |
| DMI Health Care Group, Inc. | Pinellas Park | Florida | 33782 | United States |
| Accord Clinical Research, LLC | Port Orange | Florida | 32129 | United States |
| Meridien Research | St. Petersburg | Florida | 33709 | United States |
| Clinical Research of West Florida, Inc. | Tampa | Florida | 33603 | United States |
| Stedman Clinical Trials | Tampa | Florida | 33613 | United States |
| Palm Beach Research Center | West Palm Beach | Florida | 33409 | United States |
| Pinnacle Trials Inc. | Atlanta | Georgia | 30329 | United States |
| North Georgia Premier Research | Dawsonville | Georgia | 30534 | United States |
| Best Clinical Research | Decatur | Georgia | 30034 | United States |
| Drug Studies America | Marietta | Georgia | 30060 | United States |
| Millenium Pain Center | Bloomington | Illinois | 61701 | United States |
| University of Illinois at Chicago: Department of Medicine | Chicago | Illinois | 60612 | United States |
| Apex Medical Research, AMR, Inc | Chicago | Illinois | 60616 | United States |
| Redhead Research Inc. | Peoria | Illinois | 161614 | United States |
| MediSphere Medical Research Center, LLC | Evansville | Indiana | 47714 | United States |
| Davis Clinic, PC | Indianapolis | Indiana | 46260 | United States |
| Intergrated Clinical Trial Services, Inc | West Des Moines | Iowa | 50265 | United States |
| The Pain Treatment Center of the Bluegrass | Lexington | Kentucky | 40503 | United States |
| Louisiana Research Center, LLC | Shreveport | Louisiana | 71103 | United States |
| The Willis-Knighton Interventional Pain Center | Shreveport | Louisiana | 71105 | United States |
| Pain and Rehabilitation Medicine | Bethesda | Maryland | 20814 | United States |
| Columbia Medical Practice/ RxTrials, Inc. | Columbia | Maryland | 21045 | United States |
| Brigham and Women's Hosptial | Chestnut Hill | Massachusetts | 02467 | United States |
| MedVadis Research Corporation | Wellesley Hills | Massachusetts | 02481 | United States |
| Center for Clinical Studies | Dearborn | Michigan | 48124 | United States |
| Apex Medical Research, AMR, Inc. | Flint | Michigan | 48504 | United States |
| Professional Clinical Research - Interlochen | Interlochen | Michigan | 49641 | United States |
| Beyer Research | Kalamazoo | Michigan | 49009 | United States |
| Medical Research Associates | Traverse City | Michigan | 49684 | United States |
| Center for Digestive Health | Troy | Michigan | 48098 | United States |
| MAPS Applied Research Center | Edina | Minnesota | 55435 | United States |
| Medex Healthcare Research Inc. | St Louis | Missouri | 63117 | United States |
| Montana Neuroscience Institute Foundation / Montana Spine and Pain Center | Missoula | Montana | 59802 | United States |
| Office of Stephen H. Miller, MD | Las Vegas | Nevada | 89106 | United States |
| Affiliated Clinical Research, Inc. | Las Vegas | Nevada | 89144 | United States |
| Ladder Family Practice | Las Vegas | Nevada | 89146 | United States |
| Impact Clinical Trials | Las Vegas | Nevada | 89206 | United States |
| Gastroenterology Research Associates, LLC | Cedar Knolls | New Jersey | 07927 | United States |
| Central Jersey Medical Research Center | Elizabeth | New Jersey | 07202 | United States |
| Virtua Lumberton Family Physicians | Lumberton | New Jersey | 08048 | United States |
| Holy Name Hospital | Teaneck | New Jersey | 07666 | United States |
| Long Island Gastrointestinal Research Group | Great Neck | New York | 11023 | United States |
| NYU Pain Management Center | New York | New York | 10016 | United States |
| Research Across America | New York | New York | 10022 | United States |
| University of Rochester, Pain Treatment Center | Rochester | New York | 14642 | United States |
| Upstate Clinical Research Associates | Williamsville | New York | 14221 | United States |
| Duke University Medical Center | Durham | North Carolina | 27705 | United States |
| Carolina Research | Greenville | North Carolina | 27834 | United States |
| Peters Medical Research, LLC | High Point | North Carolina | 27262 | United States |
| The Center for Clinical Research | Winston-Salem | North Carolina | 27103 | United States |
| Glenway Family Medicine | Cincinnati | Ohio | 45238 | United States |
| The Ohio State University Medical Center | Columbus | Ohio | 43210 | United States |
| Hometown Urgent Care and Research | Dayton | Ohio | 45432 | United States |
| RAS Health Ltd. | Marion | Ohio | 43302 | United States |
| COR Clinical Research, LLC | Oklahoma City | Oklahoma | 73103 | United States |
| McBride Clinic | Oklahoma City | Oklahoma | 73112 | United States |
| Memorial Clinical Research | Oklahoma City | Oklahoma | 73134 | United States |
| Pain Research of Oregon, LLC | Eugene | Oregon | 97401 | United States |
| Medford Medical Clinic, LLP | Medford | Oregon | 97504 | United States |
| Affinity Research | Portland | Oregon | 97219 | United States |
| Lehigh Gastroenterology Associates | Allentown | Pennsylvania | 18104 | United States |
| Albert Einstein Healthcare Network Einstein Pain Institute | Philadelphia | Pennsylvania | 19141 | United States |
| Jeffry A. Lindenbaum DO, PC | Yardley | Pennsylvania | 19067 | United States |
| Trident Institute of Medical Research, LLC | North Charleston | South Carolina | 29406 | United States |
| Southeastern Clinical Research | Chattanooga | Tennessee | 37403 | United States |
| Comprehensive Pain Specialists, PLLC | Hendersonville | Tennessee | 37075 | United States |
| Integrity Clinical Research, LLC | Milan | Tennessee | 38358 | United States |
| Texas Familicare Clinical Research | Hurst | Texas | 76054 | United States |
| DCOL Center for Clinical Research | Longview | Texas | 75605 | United States |
| Advanced Research Institute | Ogden | Utah | 84405 | United States |
| Highland Clinical Research | Salt Lake City | Utah | 84124 | United States |
| New River Valley Research Institute | Christiansburg | Virginia | 24073 | United States |
| Digestive and Liver Disease Specialists | Norfolk | Virginia | 23502 | United States |
| Hampton Roads Institution for Performance and Sports Medicine | Portsmouth | Virginia | 23707 | United States |
| McGuire VA Medical Center | Richmond | Virginia | 23249 | United States |
| Northwest Gastroenterology Associates | Bellevue | Washington | 98004 | United States |
| VAMC Milwaukee | Milwaukee | Wisconsin | 53295 | United States |
| Health Sciences Centre Pain Clinic | Winnipeg | Manitoba | R3A 1R9 | Canada |
| AIM Health Group London North | London | Ontario | N5X 4E7 | Canada |
| St. Michael's Hospital | Toronto | Ontario | M5B 1 W8 | Canada |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Lubiprostone | Lubiprostone: 24 mcg capsules twice daily (BID) for 36 weeks |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| ||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Mean Weekly Spontaneous Bowel Movements (SBMs) Per Month | A Spontaneous Bowel Movement (SBM) is defined as any bowel movement (BM) that did not occur within the 24-hour period following use of a rescue medication. | Intent-to-treat population with evaluable SBM data during the given month | Posted | Mean | Standard Deviation | Weekly SBMs | Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, and 9 |
|
|
| |||||||||||||||||||||||||||
| Primary | Mean Weekly Bowel Movements (BMs) Per Month | A Bowel Movement (BM) is defined as any BM (whether spontaneous or not) | Intent-to-treat population with evaluable BM data during the given month | Posted | Mean | Standard Deviation | Weekly BMs | Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, and 9 |
|
| ||||||||||||||||||||||||||||
| Secondary | Number of Participants Classified as Monthly Responders | A weekly SBM frequency rate is calculated as (168 x Number of SBMs / Number of hours observed). A participant with an SBM frequency rate between 3 and 4 was considered a moderate responder. A subject with an SBM frequency rate higher than 4 was considered a full responder. If a subject was a moderate responder or full responder for at least half the weeks in a month, then he or she was considered a monthly responder. | Intent-to-treat | Posted | Count of Participants | Participants | Months 1, 2, 3, 4, 5, 6, 7, 8, and 9 |
|
| |||||||||||||||||||||||||||||
| Secondary | Straining Associated With Spontaneous Bowel Movements by Month | Participants rate the straining associated with the SBM on a scale where 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe The highest score is 4, and lower scores are better. | Intent-to-treat with evaluable data at the given time point | Posted | Mean | Standard Deviation | score on a scale | Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, and 9 |
|
| ||||||||||||||||||||||||||||
| Secondary | Stool Consistency of Spontaneous Bowel Movements by Month | Participants rate each spontaneous bowel movement on a scale where 0 = very loose, 1 = loose, 2 = normal, 3 = hard, 4 = very hard (little balls) The highest score is 4, but the best score is 2. | Intent-to-treat with evaluable data at the given time point | Posted | Mean | Standard Deviation | score on a scale | Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, and 9 |
|
| ||||||||||||||||||||||||||||
| Secondary | Constipation Severity by Month | Participants rate the severity of their constipation on a scale where 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe. The highest score is 4, but the best score is 0. | Intent-to-treat with evaluable scores at the given time point | Posted | Mean | Standard Deviation | score on a scale | Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, and 9 |
|
| ||||||||||||||||||||||||||||
| Secondary | Abdominal Bloating by Month | Participants rate their bloating on a scale where 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe. The highest score is 4, but the best score is 0. | Intent-to-treat with evaluable data at the given time point | Posted | Mean | Standard Deviation | score on a scale | Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, and 9 |
|
| ||||||||||||||||||||||||||||
| Secondary | Abdominal Discomfort by Month | Participants rate their abdominal discomfort on a scale where 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe. The highest score is 4, but the best score is 0. | Intent-to-treat with evaluable data at the given time point | Posted | Mean | Standard Deviation | score on a scale | Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, and 9 |
|
| ||||||||||||||||||||||||||||
| Secondary | Bowel Habit Regularity by Month | Participants rate their bowel habit regularity on a balanced scale of 1 to 7 where 1=Very Regular and 7=Very Irregular. The highest score is 7, but the best score is 1. | Intent-to-treat with evaluable data at the given time point | Posted | Mean | Standard Deviation | score on a scale | Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, and 9 |
|
| ||||||||||||||||||||||||||||
| Secondary | Treatment Effectiveness by Month | Participants rate treatment effectiveness on a scale where 0 = not at all effective, 1 = a little bit effective, 2 = moderately effective, 3 = quite a bit effective, 4 = extremely effective. The highest and best score is 4. | Intent-to-treat with evaluable data at the given time point | Posted | Mean | Standard Deviation | score on a scale | Months 1, 2, 3, 4, 5, 6, 7, 8, and 9 |
|
| ||||||||||||||||||||||||||||
| Secondary | Mean Weekly Complete SBMs by Month | Participants rate each SBM as complete if their bowels feel completely empty after the SBM | Intent-to-treat with evaluable data at the time point | Posted | Mean | Standard Deviation | Weekly Complete SBMs | Months 1, 2, 3, 4, 5, 6, 7, 8, and 9 |
|
| ||||||||||||||||||||||||||||
| Secondary | Mean Weekly Complete BMs by Month | Participants rate each BM as complete if their bowels feel completely empty after the BM | Intent-to-treat with evaluable data at the time point | Posted | Mean | Standard Deviation | Weekly Complete BMs | Months 1, 2, 3, 4, 5, 6, 7, 8, and 9 |
|
|
9 months plus 7 days for follow-up
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | All Participants | Lubiprostone: 24 mcg capsules twice daily (BID) for 9 months | 1 | 439 | 34 | 439 | 100 | 439 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Gastroenteritis | Infections and infestations | MedDRA 13.1 | Systematic Assessment |
| |
| Cellulitis | Infections and infestations | MedDRA 13.1 | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA 13.1 | Systematic Assessment |
| |
| Papilloma Viral Infection | Infections and infestations | MedDRA 13.1 | Systematic Assessment |
| |
| Osteomyelitis | Infections and infestations | MedDRA (13.1) | Systematic Assessment |
| |
| Nocardiosis | Infections and infestations | MedDRA (13.1) | Systematic Assessment |
| |
| Meningitis Aseptic | Infections and infestations | MedDRA (13.1) | Systematic Assessment |
| |
| Appendicitis | Infections and infestations | MedDRA (13.1) | Systematic Assessment |
| |
| Abscess Limb | Infections and infestations | MedDRA (13.1) | Systematic Assessment |
| |
| Septic Shock | Infections and infestations | MedDRA (13.1) | Systematic Assessment |
| |
| Abdominal Abcess | Infections and infestations | MedDRA (13.1) | Systematic Assessment |
| |
| Respiratory Failure | Respiratory, thoracic and mediastinal disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Pulmonary Embolism | Respiratory, thoracic and mediastinal disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Pleural Effusion | Respiratory, thoracic and mediastinal disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Asthma | Respiratory, thoracic and mediastinal disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Lumbar Spinal Stenosis | Musculoskeletal and connective tissue disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Intervertebral Disc Protrusion | Musculoskeletal and connective tissue disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Costochondritis | Musculoskeletal and connective tissue disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Back Pain | Musculoskeletal and connective tissue disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Coranary Artery Disease | Cardiac disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Myocardial Infarction | Cardiac disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Atrial Fibrillation | Cardiac disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Pain | General disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Oedema Peripheral | General disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Non-Cardiac Chest Pain | General disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Pancreatitis | Gastrointestinal disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Oesophageal Mass | Gastrointestinal disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Abdominal Adhesions | Gastrointestinal disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Mental Status Changes | Psychiatric disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Depression | Psychiatric disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Anxiety | Psychiatric disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Cognitive Disorder | Nervous system disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Spinal Compression Fracture | Injury, poisoning and procedural complications | MedDRA (13.1) | Systematic Assessment |
| |
| Road Traffic Accident | Injury, poisoning and procedural complications | MedDRA (13.1) | Systematic Assessment |
| |
| Multiple Fractures | Injury, poisoning and procedural complications | MedDRA (13.1) | Systematic Assessment |
| |
| Cholelithiasis | Hepatobiliary disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Cholecystitis Acute | Hepatobiliary disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Cholecystitis | Hepatobiliary disorders | MedDRA 13.1 | Systematic Assessment |
| |
| Pancytopenia | Blood and lymphatic system disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Jugular Vein Thrombosis | Vascular disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Renal Failure Acute | Renal and urinary disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Lung Neoplasm Malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (13.1) | Systematic Assessment |
| |
| Chronic Obstructive Pulmonary Disease | Respiratory, thoracic and mediastinal disorders | MedDRA (13.1) | Systematic Assessment |
| |
| Pulmonary Cavitation | Respiratory, thoracic and mediastinal disorders | MedDRA (13.1) | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nausea | Gastrointestinal disorders | MedDRA 13.1 | Systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA 13.1 | Systematic Assessment |
| |
| Upper Respiratory Tract Infection | Infections and infestations | MedDRA (13.1) | Systematic Assessment |
| |
| Back Pain | Musculoskeletal and connective tissue disorders | MedDRA (13.1) | Systematic Assessment |
|
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| VP, Clinical Development | Sucampo Pharma Americas, LLC | 301-961-3400 | info@sucampo.com |
| ID | Term |
|---|---|
| D000079689 | Opioid-Induced Constipation |
| ID | Term |
|---|---|
| D003248 | Constipation |
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D000079524 | Narcotic-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068238 | Lubiprostone |
| ID | Term |
|---|---|
| D000527 | Alprostadil |
| D005229 | Fatty Acids, Monounsaturated |
| D005231 | Fatty Acids, Unsaturated |
| D005227 | Fatty Acids |
| D008055 | Lipids |
Not provided
Not provided
|
| Month 2 |
|
|
| Month 3 |
|
|
| Month 4 |
|
|
| Month 5 |
|
|
| Month 6 |
|
|
| Month 7 |
|
|
| Month 8 |
|
|
| Month 9 |
|
|
| Title | Denominators | Categories |
|---|
| Baseline |
|
| ||||
| Month 1 |
|
| ||||
| Month 2 |
|
| ||||
| Month 3 |
|
| ||||
| Month 4 |
|
| ||||
| Month 5 |
|
| ||||
| Month 6 |
|
| ||||
| Month 7 |
|
| ||||
| Month 8 |
|
| ||||
| Month 9 |
|
|
|
|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
| Baseline |
|
| ||||
| Month 1 |
|
| ||||
| Month 2 |
|
| ||||
| Month 3 |
|
| ||||
| Month 4 |
|
| ||||
| Month 5 |
|
| ||||
| Month 6 |
|
| ||||
| Month 7 |
|
| ||||
| Month 8 |
|
| ||||
| Month 9 |
|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
| Baseline |
|
| ||||
| Month 1 |
|
| ||||
| Month 2 |
|
| ||||
| Month 3 |
|
| ||||
| Month 4 |
|
| ||||
| Month 5 |
|
| ||||
| Month 6 |
|
| ||||
| Month 7 |
|
| ||||
| Month 8 |
|
| ||||
| Month 9 |
|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
| Baseline |
|
| ||||
| Month 1 |
|
| ||||
| Month 2 |
|
| ||||
| Month 3 |
|
| ||||
| Month 4 |
|
| ||||
| Month 5 |
|
| ||||
| Month 6 |
|
| ||||
| Month 7 |
|
| ||||
| Month 8 |
|
| ||||
| Month 9 |
|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
| Baseline |
|
| ||||
| Month 1 |
|
| ||||
| Month 2 |
|
| ||||
| Month 3 |
|
| ||||
| Month 4 |
|
| ||||
| Month 5 |
|
| ||||
| Month 6 |
|
| ||||
| Month 7 |
|
| ||||
| Month 8 |
|
| ||||
| Month 9 |
|
|
|
| Title | Denominators | Categories |
|---|
| Month 1 |
|
| ||||
| Month 2 |
|
| ||||
| Month 3 |
|
| ||||
| Month 4 |
|
| ||||
| Month 5 |
|
| ||||
| Month 6 |
|
| ||||
| Month 7 |
|
| ||||
| Month 8 |
|
| ||||
| Month 9 |
|
|
| Title | Denominators | Categories |
|---|
| Month 1 |
|
| ||||
| Month 2 |
|
| ||||
| Month 3 |
|
| ||||
| Month 4 |
|
| ||||
| Month 5 |
|
| ||||
| Month 6 |
|
| ||||
| Month 7 |
|
| ||||
| Month 8 |
|
| ||||
| Month 9 |
|
|